Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for cognitive impairment in Alzheimer's disease
ChiCTR2200061763Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide in Alzheimer's disease (AD) (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: CDR-SB score, fasting blood glucose and 1 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2200061763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061763.